David Amsellem
Stock Analyst at Piper Sandler
(4.75)
# 135
Out of 4,981 analysts
152
Total ratings
63.87%
Success rate
22.28%
Average return
Main Sectors:
Stocks Rated by David Amsellem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SUPN Supernus Pharmaceuticals | Maintains: Neutral | $36 → $40 | $45.47 | -12.03% | 16 | Aug 29, 2025 | |
| AMGN Amgen | Maintains: Overweight | $328 → $342 | $276.39 | +23.74% | 5 | Aug 25, 2025 | |
| BIIB Biogen | Maintains: Neutral | $115 → $118 | $144.86 | -18.54% | 2 | Aug 14, 2025 | |
| ABBV AbbVie | Assumes: Overweight | $231 | $218.34 | +5.80% | 1 | Aug 12, 2025 | |
| AMPH Amphastar Pharmaceuticals | Maintains: Neutral | $30 → $25 | $28.06 | -10.91% | 9 | Aug 8, 2025 | |
| CORT Corcept Therapeutics | Maintains: Overweight | $131 → $121 | $72.87 | +66.05% | 8 | Aug 1, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $154 → $175 | $141.90 | +23.33% | 11 | Jul 31, 2025 | |
| OGN Organon & Co. | Maintains: Overweight | $24 → $18 | $10.65 | +69.01% | 6 | May 15, 2025 | |
| COLL Collegium Pharmaceutical | Reiterates: Neutral | $36 → $37 | $37.33 | -0.88% | 8 | May 9, 2025 | |
| JAZZ Jazz Pharmaceuticals | Reiterates: Overweight | $176 → $147 | $126.16 | +16.52% | 14 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $65 | $46.20 | +40.69% | 1 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3 → $4 | $7.49 | -46.60% | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $13 | $23.21 | -43.99% | 5 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 → $10 | $9.96 | +0.40% | 7 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $30 | $19.93 | +50.53% | 10 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $13 | $15.40 | -15.58% | 5 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $11 | $9.99 | +10.11% | 4 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $38 → $37 | $26.97 | +37.19% | 7 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $68 | $97.95 | -30.58% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $9 → $3 | $7.26 | -58.68% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 | $27.12 | +54.87% | 10 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $10 | $5.05 | +98.02% | 1 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $21 | $1.31 | +1,503.05% | 3 | Feb 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $90 → $113 | $118.42 | -4.58% | 3 | Jan 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $42 | $32.39 | +29.67% | 3 | Oct 16, 2023 |
Supernus Pharmaceuticals
Aug 29, 2025
Maintains: Neutral
Price Target: $36 → $40
Current: $45.47
Upside: -12.03%
Amgen
Aug 25, 2025
Maintains: Overweight
Price Target: $328 → $342
Current: $276.39
Upside: +23.74%
Biogen
Aug 14, 2025
Maintains: Neutral
Price Target: $115 → $118
Current: $144.86
Upside: -18.54%
AbbVie
Aug 12, 2025
Assumes: Overweight
Price Target: $231
Current: $218.34
Upside: +5.80%
Amphastar Pharmaceuticals
Aug 8, 2025
Maintains: Neutral
Price Target: $30 → $25
Current: $28.06
Upside: -10.91%
Corcept Therapeutics
Aug 1, 2025
Maintains: Overweight
Price Target: $131 → $121
Current: $72.87
Upside: +66.05%
Neurocrine Biosciences
Jul 31, 2025
Maintains: Overweight
Price Target: $154 → $175
Current: $141.90
Upside: +23.33%
Organon & Co.
May 15, 2025
Maintains: Overweight
Price Target: $24 → $18
Current: $10.65
Upside: +69.01%
Collegium Pharmaceutical
May 9, 2025
Reiterates: Neutral
Price Target: $36 → $37
Current: $37.33
Upside: -0.88%
Jazz Pharmaceuticals
May 7, 2025
Reiterates: Overweight
Price Target: $176 → $147
Current: $126.16
Upside: +16.52%
Apr 22, 2025
Initiates: Overweight
Price Target: $65
Current: $46.20
Upside: +40.69%
Mar 7, 2025
Reiterates: Neutral
Price Target: $3 → $4
Current: $7.49
Upside: -46.60%
Mar 6, 2025
Maintains: Overweight
Price Target: $16 → $13
Current: $23.21
Upside: -43.99%
Mar 5, 2025
Reiterates: Neutral
Price Target: $14 → $10
Current: $9.96
Upside: +0.40%
Jan 17, 2025
Maintains: Overweight
Price Target: $23 → $30
Current: $19.93
Upside: +50.53%
Jan 10, 2025
Maintains: Overweight
Price Target: $24 → $13
Current: $15.40
Upside: -15.58%
Nov 11, 2024
Maintains: Overweight
Price Target: $9 → $11
Current: $9.99
Upside: +10.11%
Oct 25, 2024
Reiterates: Overweight
Price Target: $38 → $37
Current: $26.97
Upside: +37.19%
Oct 11, 2024
Initiates: Overweight
Price Target: $68
Current: $97.95
Upside: -30.58%
Aug 2, 2024
Downgrades: Underweight
Price Target: $9 → $3
Current: $7.26
Upside: -58.68%
Jul 3, 2024
Maintains: Overweight
Price Target: $42
Current: $27.12
Upside: +54.87%
Apr 11, 2024
Initiates: Overweight
Price Target: $10
Current: $5.05
Upside: +98.02%
Feb 16, 2024
Maintains: Overweight
Price Target: $20 → $21
Current: $1.31
Upside: +1,503.05%
Jan 16, 2024
Maintains: Overweight
Price Target: $90 → $113
Current: $118.42
Upside: -4.58%
Oct 16, 2023
Maintains: Overweight
Price Target: $72 → $42
Current: $32.39
Upside: +29.67%